Ioxilan
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| Image:Ioxilan.png | |
| Ioxilan
| |
| Systematic (IUPAC) name | |
| 5-(acetyl-(2,3-dihydroxypropyl)amino)-N'-(2,3-dihydroxypropyl)-N-(2-hydroxy ethyl)-2,4,6-triiodo-benzene-1,3-dicarboxamide | |
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | |
| Chemical data | |
| Formula | C18H24I3N3O8 |
| Mol. mass | 791.112 |
| Pharmacokinetic data | |
| Bioavailability | N/A |
| Protein binding | negligible |
| Metabolism | ? |
| Half life | 2 hours |
| Excretion | Mostly renal |
| Therapeutic considerations | |
| Pregnancy cat. |
B(US) |
| Legal status | |
| Routes | intravenously |
Ioxilan is a diagnostic contrast agent. It is injected intravenously before taking X-ray images to increase arterial contrast in the final image. It is marketed under the trade name Oxilan by Guerbet, L.L.C.
 | This pharmacology-related article is a stub. You can help WikiDoc by expanding it. |
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
